MSFT 430.95 1.7688% AAPL 239.625 0.967% NVDA 137.9692 -0.2031% GOOGL 172.05 1.8349% GOOG 173.58 1.8124% AMZN 210.79 1.395% META 593.04 3.2595% AVGO 166.86 2.9492% TSLA 357.2187 3.4937% TSM 194.225 5.1798% LLY 801.2078 0.7365% V 315.94 0.2729% JPM 246.3 -1.3695% UNH 607.76 -0.3999% NVO 108.925 1.9897% WMT 92.555 0.0595% LVMUY 127.99 2.9686% XOM 117.79 -0.1441% LVMHF 645.0 3.8221% MA 530.27 -0.501%
The Offer
Company Overview
Heart Test Laboratories, Inc. was incorporated in Texas, the USA in August 2007, and operates as a medical technology company by deploying innovative AI-based solution technology to ECG (also termed as EKG) for enhancing the ECG’s clinical usefulness. The company is majorly inclined toward making the ECG an effective tool for cardiac screening, especially in the frontline or point-of-care clinical settings. The company’s first product MyoVista wavECG (MyoVista), is a 12- lead resting ECG which is also aimed to yield diagnostic information about cardiac dysfunction which was earlier only available through cardiac imaging and is waiting for the FDA clearance. The business model is devised around the sale of MyoVista and the usage of the proprietary supplies that are electrodes that will be required for each test, ‘razor-razorable’. Post-FDA approval the group aims to cater to the frontline healthcare in the US which includes cardiology, and primary care to help the physician for making conclusions in referring cardiology process, retail clinics, and insurers.
Key Highlights
Primary Offering: The company is offering units of securities, issuing 1,750,000 Units at USD 5.00 per Unit (which is the midpoint of the price range set in the IPO prospectus), each Unit consisting of: a) One share of Common Stock; and b) One Warrant to purchase one share of Common Stock. The Warrants may only be exercised at an exercise price of USD 5.00 per whole share of Common Stock. The Common Stock and the Warrants comprising the Units are immediately separable upon issuance and will be issued separately but will be purchased together in this offering.
Use of Proceeds: The group estimates the net proceeds from this offering will be approximately USD 7.2 million, assuming an initial public offering price of USD 5.00 per Common Share (which is the midpoint of the range set). The company has estimated an approx. of USD 8.4 million of the proceeds if the underwriters exercise the option of over-allotment in full. The company intends to use these proceeds for achieving FDA clearance for the MyoVista device, then the reaming will be allocated to research & development, completing the pivotal clinical study for the validation, working capital, and general corporate purposes, etc.
Dividend Policy: Since its inception, the group has never paid any dividend and does not intend to pay dividends on its Common Shares anytime soon.
Sector Overview
Financial Highlights (expressed in thousands USD):
Source: IPO Prospectus
Key Management Highlights
Source: IPO Prospectus
Risk Associated (High)
Investment in the IPO of "HSCS" is exposed to a variety of risks such as:
Conclusion
Since incorporation, the company has raised funds through the sale of equity and the issue of debt securities. The company’s first product: MyoVista is waiting for the clearance from FDA, post that the group will start the business operation on a normal scale. Any failure to obtain the license can cause the business to fail. The medical testing equipment and ESG devices industry are set to expand at a rapid pace and the company’s technology to keep itself in the market pace is impressive. The financials of the company as of now are weak, but any pivotal favorable change in terms of the approval from the FDA can turn the financials of the company in its favor. Also, the makrt is quite volatile on the back of rising interest rates, geopolitical issues, supply chain related issues, rising shipping costs and inflationary pressure, which could have a weigh on the HSCS’s IPO performance. Hence, Heart Test Laboratories, Inc. IPO looks "Neutral” at the current price and in the present market scenario, given the associated risks.
Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.
Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.